Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IN9G
|
|||
| Former ID |
DIB012451
|
|||
| Drug Name |
Liatermin
|
|||
| Synonyms |
RGDNF; GDNF, Amgen; Glial derived neurotrophic factor, Amgen/Medtronic
Click to Show/Hide
|
|||
| Indication | Lateral sclerosis [ICD-11: 8B61] | Phase 1/2 | [1] | |
| Company |
Amgen Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glial cell line-derived neurotrophic factor (GDNF) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00111982) Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.